Video Gallery

Navigating COVID-19 & Vaccinations

Keeping Residents & Families Connected

Vivage and WellAge Senior Living continue to work diligently to implement heightened Infection Control and Prevention in all of our communities.

We also recognize the increased importance of connectivity and communication during these times, which is why we utilize an innovative platform called LifeLoop. This tool is designed to engage family members and most of our individual communities send out regular updates through this system to keep families involved and updated.

Routine COVID Testing Being Conducted at Vivage and WellAge

Residents and employees residing and working in a community setting are at higher risk for infection from COVID-19. Testing for SARS-CoV-2, the virus that causes COVID-19, detects current infections among residents and employees. Vivage and WellAge conduct COVID PCR (polymerase chain reaction) testing aimed at preventing SARS-CoV-2 from entering communities, detecting cases quickly, and slowing transmission on a routine basis. The PCR test is the “gold standard” test for diagnosing COVID-19 because it’s the most accurate and reliable test.

All of our communities follow CDC, state, and local health department guidelines for conducting routine COVID testing for employees and residents.

COVID Vaccines Being Given to Employees and Residents at Vivage and WellAge Communities

Vivage and Wellage communities have started to receive the much anticipated COVID vaccine. Clinics are being conducted by CVS and Walgreens. The majority of the communities at this time are receiving the Pfizer shot that is a two-shot process, with the second shot being given 21 days after the first shot. The vaccines offer a ray of hope. There is a tremendous amount of relief and excitement about being able to be part of the first phase in the fight against COVID.

All of our communities follow CDC, state, and local health department guidelines for conducting routine COVID testing for employees and residents.

Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)

LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, potentially preventing and treating COVID-19.

Vivage is excited to be a part of this first-of-its-kind study involving up to 2,400 residents and staff at long-term care facilities in the U.S.

Learn More

Tools & Resources